Oxfordshire Bioscience Network - PRWeb Press Release Account Feed http://www.rsspad.com/rss2a/232432.xml Oxfordshire Bioscience Network - Press Releases en xml@emediawire.com xml@emediawire.com 30 Oxford BioMedica develops strategic development plan with the commercialisation of TroVax http://www.prweb.com/releases/2008/03/prweb781194.htm BioTrinity 2008 - Oxford today announces a highly relevant new addition to its programme. Oxfordshire Bioscience Networks' leading partnering and networking event confirmed that Peter Nolan, SVP Commercial Development at Oxford BioMedica, will discuss the company's deal with sanofi-aventis to develop and commercialise TroVax® for the treatment and prevention of cancers. This follows the announcement that the TRIST trial successfully completed patient enrolment. (PRWeb Mar 18, 2008)

Read the full story at http://www.prweb.com/releases/2008/03/prweb781194.htm

]]> http://www.prweb.com/releases/2008/03/prweb781194.htm Financing Alternatives for Biotechs Will be a Key Feature on the Programme: Over 300 Companies Expected at BioTrinity 2008 - Oxford http://www.prweb.com/releases/biotechnology/partnering/prweb745914.htm Continuing the success of last year, BioTrinity 2008 has already secured registration from over 150 companies. The biopartnering event, lead by Oxfordshire Bioscience Network (OBN) takes place between the 15th and 16th April in Oxford, UK. This year's agenda features an international panel of financial specialists in the biotech arena. (PRWeb Mar 6, 2008)

Read the full story at http://www.prweb.com/releases/biotechnology/partnering/prweb745914.htm

]]> http://www.prweb.com/releases/biotechnology/partnering/prweb745914.htm Biotech Advances in the Spotlight at BioTrinity 2008 http://www.prweb.com/releases/2008/02/prweb682223.htm BioTrinity, Oxfordshire Bioscience Networks' leading partnering and networking event, will this year focus on the current trends and latest issues affecting the UK's fast growing biotech industry. (PRWeb Feb 8, 2008)

Read the full story at http://www.prweb.com/releases/2008/02/prweb682223.htm

]]> http://www.prweb.com/releases/2008/02/prweb682223.htm Announcing BioTrinity 2008 and the Billion Euro BioCluster http://www.prweb.com/releases/2008/02/prweb663744.htm The 2nd annual Oxford biopartnering conference, BioTrinity 2008, is looming large on the biopartnering calender -- and with 11 weeks to go, it is again expected to be the largest biotech partnering conference the region has seen, with over 300 companies expected to take part. (PRWeb Feb 4, 2008)

Read the full story at http://www.prweb.com/releases/2008/02/prweb663744.htm

]]> http://www.prweb.com/releases/2008/02/prweb663744.htm BioTrinity Marks the Resurgence of the Oxford and South East Biotech Industry http://www.prweb.com/releases/2007/04/prweb518279.htm The inaugural http://www.biotrinity.com [biotech partnering conference __title__ BioTrinity] was a great success, becoming the largest biotech & healthcare partnering conference in the Oxford and South East biotech region, with over 400 delegates, 285 companies, 180 licensing opportunities and 520 one-to-one partnering meetings scheduled. (PRWeb Apr 16, 2007)

Read the full story at http://www.prweb.com/releases/2007/04/prweb518279.htm

]]> http://www.prweb.com/releases/2007/04/prweb518279.htm Europe's Largest Life Science Fund to Take Part in Biotrinity 2007: Panel to Discuss How to Attract Globally Focussed Investment http://www.prweb.com/releases/2007/02/prweb504896.htm The keys to successfully attracting globally focussed investment will be the main topic of discussion for the VC panel at BioTrinity 2007. Tim Haines, a partner at Abingworth, the international life sciences investment group which raised Europe's largest ever life sciences venture fund ($587 million Abingworth Bioventures V LP), has announced that he will join the VC panel discussion. (PRWeb Feb 14, 2007)

Read the full story at http://www.prweb.com/releases/2007/02/prweb504896.htm

]]> http://www.prweb.com/releases/2007/02/prweb504896.htm $360m Deal-making CEO of Oxford-based Prosidion to Address BioTrinity http://www.prweb.com/releases/2007/01/prweb499880.htm CEO of UK-based subsidiary of (OSI) Pharmaceuticals to present at a new biotechnology partnering conference which will showcase companies from the most successful biotech super-cluster in Europe, which has raised more in IPO, second round and private equity financing than any other region in recent years. (PRWeb Jan 29, 2007)

Read the full story at http://www.prweb.com/releases/2007/01/prweb499880.htm

]]> http://www.prweb.com/releases/2007/01/prweb499880.htm De Facto Chosen to Boost Profile of the Oxfordshire Bioscience Network http://www.prweb.com/releases/2006/12/prweb493089.htm Oxfordshire Bioscience Network appoints De Facto as its communications partner to raise its profile within the pharma-biotech sector moving forward. (PRWeb Dec 21, 2006)

Read the full story at http://www.prweb.com/releases/2006/12/prweb493089.htm

]]> http://www.prweb.com/releases/2006/12/prweb493089.htm